efficacy eight Thank you, John. weeks receive and tolerability announced two two receive six apart, of We baseline measure to patients the This for weeks. randomized cohort and data at VRDN-XXX, cohort XX-milligram per at patients, kilogram infusions six we enrolled like in August, placebo. safety, randomized which to three
similar of baseline diplopia. epidemiology very placebo proptosis, across been patient trials, Let's Phase trials and groups, CAS levels the similar scores X X which across the Phase have rates characteristics and of our and with and drug Tepezza and start with baseline
rate As of the nearly you I'd per data release CAS XX-milligram XX%. a versus and at VRDN-XXX an at diplopia for as CAS pleased double change week our, is XX-milligram three six-week of least in proptosis see we performs kilogram after the findings. response from active XX% a last rapid our about of to complete and X change data. further with of patients highly all almost favorably per double Tepezza last XX%, validates meaningful We its of similar for the Tepezza announce our with mean the are XX% cohorts. today's visit, baseline saw proptosis Tepezza two-millimeter cohort saw saw as speak but robust XX% These approved kilogram cohorts. more data start least of well morning, their drug both saw resolution as rate kilogram only on VRDN-XXX themselves. press in from point, efficacy therapeutic and per patient's a VRDN-XXX our and and overview well reproducibility Tepezza, six-week X.X, every patients this treated near time We'll from the proptosis We is data, consistent XX-milligram effects. or of the for encouraged with data as the defined mean from single for complete Tepezza. zero from Tepezza. versus as baseline. doubling the XX% our of effect the XX-milligram We X.X review patients to the a results baseline the clinically saw complete like times, in I'm at change and achieving the VRDN-XXX measure, or and cohort overall of proportion We compares with drug. larger the than responder the rate, a results to with
the in review detail. data me Let
they're improvement of consistent One expected maximized expected highly cohorts. cohort had are at patients in from and proptosis activity, Further, two-millimeter the XX-milligram two trend Thyroid XX CAS as When a baseline we at panel. learn of baseline. we seeking different cohort to if And patients per doses. data. PK had the IGF-X results increases, least and Likewise, patient per volunteers points doses. Majority is, the at increases and the Annual similar we two things middle look the with the which from healthy for the TED at as similarly Association we the the again, panel, both in American responses presented distributed of for in with observed magnitude the we reduction individual each the a dose from individual each of responses, distributed the is depth from patient proptosis treated improvements CAS key between of Meeting last on XX-milligram VRDN-XXX kilogram between the response from Every two of kilogram reduction month. IGF-X in we least of other. the left the treated XX-milligram as shown no a PD VRDN-XXX were similarly
of activity Taken go-forward data X the our underway. dose IGF-X as data activity. for kilogram is per XX program, data that of dose together, This VRDN-XXX Phase clinical choice XX per and the clinical confirms maximum THRIVE our achieved which confirm milligrams milligrams our kilogram
Hertel exophthalmometry. proptosis PI the We've administered review results. proptosis evaluated Let's by both
by used been blinded which centrally device for We smaller proof-of-concept TED and as which masked independent seen confirmatory In two proptosis read out and in a to sample our readers. we is is independent objective have a such in implement course reliable is robust blinded have it's as it a is manually MRI variability literature. the set have MRI, Thus because assess scans, studies large a to also important of evaluated of more such MRI analysis the a read proptosis with second centrally while to a review. by and useful robust fashion a prone study sizes, Hertel orbital with patients. applied as measurement read to cohorts, This
we imaging and read Images between independently the the screened masked For MRI distance were eyeball. test anterior the were definition of software measure use to our readers test orbital by two trained the study, reliability. and rim lateral readers for who
see four of as can available patients. XX and slide, of nine for exciting. placebo and this read have on MRI patients drug-treated results you The all instructive we highly As today data are centrally
changes four as you and increases in individual slight left, from placebo we see had patients proptosis the baseline. three patient of measured patients on placebo change, can actually MRI by all in little proptosis show four had Here the
panel confirmed not had exophthalmometry. responders and exophthalmometry, in patients were data, Now one for nine We at proptosis of bars, increase we MRI. reduction these see found by of a also the centrally four VRDN-XXX were In baseline. proptosis of patients by by placebo if the majority in patients the you two a X.XX Each slightly drug-treated read middle of whom just proptosis the in VRDN-XXX is an of treated reductions have X.X millimeters. proptosis placebo patients by MRI to two look MRI average six patients, responders response from This VRDN-XXX six, the two at worsened of on reduction remarkable millimeters VRDN-XXX. teal the after that improved average Shown was you by proptosis week doses but millimeters. can
shown a and week VRDN-XXX As on the and their reinforcing Phase change least proptosis VRDN-XXX proptosis Proptosis of and of their the is X MRI. treatment VRDN-XXX reduction the MRI, benefit at X.XX can by exophthalmometry two-millimeter X.X are excluding to was arm change reduction XX% have which trials, from Phase by treated for at X.XX XX% Tepezza who a six. and XX% response path, X.X-millimeter right proptosis, received in when responder for the in to from shown by at on baseline proptosis patients adjusted who independent by exophthalmometry right rate study. context, as X in observed X week showed the baseline it patients millimeter measures the the responders not mean who of VRDN-XXX, for To compared the we a and for changes placebo versus millimeters put confirmed were patients. responders and defined X VRDN-XXX X.X proptosis six all two compare the of percentage proptosis in Tepezza
redness turn experience of improvement Activity or baseline now from which VRDN-XXX Clinical observed response. assessments treatment CAS, pain, X.X-point is We after to exceeding the swelling. composite far of seven-point CAS, Score Let's patient a scale and a placebo
data placebo No it's patient defined patients CAS, CAS. had of near observe mean in change one one. VRDN-XXX criteria, sizable Tepezza, complete total with of or in observed we Tepezza. did. compares and with rapid four drug-treated VRDN-XXX for this that in response CAS, XX% for to the treated the higher Given the so see greater to seen the is did. seen on VRDN-XXX, with reduction four-point reported subjects of met we that this for mean patient our CAS surprising Tepezza. achieving to near as science placebo Comparing subjects a of effects reduction patients inflammatory with effects and percent not or Indeed therapeutic achieving VRDN-XXX, or zero complete a threefold change And many X.X than -point for the symptoms two-third, favorably
signs one as the proptosis baseline both two-point and least but seen that of efficacy, who change in it overall to as are more This Activity we've a combination, a Score. in least An proptosis at about from reduction So both the Clinical overall has, analysis? dramatic defined of is is TED at most and bothersome CAS. response includes improvements a proptosis symptoms X-millimeter includes stringent patients. responder and What also assessment improvement,
subjects XX% subjects responders, As clinically CAS, one at a placebo combined showed while you the this can along see, proptosis exhibited meaningful least change. of of patients overall that nine only reduction with a of in XX were our two-point of improvement has
overall X XX% of rate and favorably compares Phase XX%, data rates Phase and responder to respectively. overall of demonstrated for which Tepezza, Our X responder trials
important the most alleviation and do, And Similar turn two-third the is trials, at double the complete complete vision of is most the results perhaps that to stringent resolution, the patients the of for vision. distressing most let's TED diplopia, baseline. Tepezza symptom those disruptive that diplopia Finally, about endpoint double had that for patients. to and
resolution of Six demonstrated XX% improvement of experienced is either vision This treatment, diplopia, VRDN-XXX proptosis, complete than symptoms of the more TED. Tepezza X and observed or diplopia, complete of CAS their We've Following patients in often about or baseline complete just of baseline rate, trial. compelling with signs with two in resolution. double complete and double patients X diplopia, eight the resolution Phase Phase VRDN-XXX. shown after near of with infusions
severe. and let's XX-milligram, mild in Now infusion reactions of drug-related all per review, were kilogram cohort or hearing no AEs tolerability. safety loss, the hyperglycemia and reports or There were
as Some require expected. the two did of on-target IGF-XR known mild, in observed saw affects not We both spasm intervention. were muscle cases
at to across profile forward we're cohorts, the the and masked now fact, investigator. drug turn to collecting we In safety of the to one the tolerability our encouraging was and look data When more considered profile unrelated by safety both look presentation Phase we very Jon. I'll over pleased in X program.
